相关实验视频
Updated: Jul 19, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.9K
在高脂肪饮食诱导的肥胖小鼠中,使用他类药物或阻断PCSK9可缓解气道过敏反应和肺纤维化
Lin Liang1,2, Sook In Chung2, Tae-Eun Guon2
1Graduate School of Medicine, Yonsei University College of Medicine, Seoul, Korea.
Respiratory research
|May 18, 2024
概括
降脂药物如他类药物和阿利罗马布可以减少与肥胖相关的呼吸道过敏反应和肺纤维化. 这些治疗向炎症和纤维化通路,为肥胖的喘患者提供潜在的好处.
科学领域:
- 肺部医学 肺部医学
- 心血管药理学心血管药理学
背景情况:
- 肥胖会加剧气道过敏反应和肺纤维化,使喘管理复杂化.
- 类药物和PCSK9抑制剂降低脂质,并具有抗炎和氨酸-血管酶系统抑制的特性.
研究的目的:
- 为了研究阿托瓦斯塔丁和阿利罗库马布对肥胖引起的气道过敏反应和肺纤维化的影响.
- 探索这些降脂剂对肺部炎症和纤维化通路的影响.
主要方法:
- 在使用高脂肪饮食的C57BL/6小鼠中诱导肥胖.
- 小鼠接受阿托瓦斯塔丁或阿利罗马布,以评估对气道过敏反应和肺病理的影响.
主要成果:
- 肥胖增加了呼吸道的高反应性,肺纤维化和亲炎性介质.
- 阿托瓦斯塔丁和阿利罗库马布减弱了这些标记物,降低了血清瘦素和自由脂肪酸,并抑制了TGF-β1,IL-1β,IL-6和IL-17a.
- 这些药物还降低了氨酸- ангиотензин系统 (RAS),NLRP3炎症组和肺组织中的胆囊托基宁活性.
结论:
- 降脂疗法显示出减轻与肥胖相关的呼吸道过敏反应和肺纤维化方面的潜力.
- 抑制NLRP3炎症酶,RAS和胆囊托基宁活性是关键机制.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

